專注醫(yī)療健康產(chǎn)業(yè)投資及家族資產(chǎn)管理
歷任：美國(guó)上市制藥公司中國(guó)區(qū)總裁?(公司研發(fā)產(chǎn)品成功授權(quán)給Novartis、臺(tái)灣藥品管理管制局、…等)；生技育成中心、工研院生醫(yī)所、制藥工業(yè)同業(yè)公會(huì)及創(chuàng)業(yè)投資商業(yè)同業(yè)公會(huì) 顧問(wèn)！管理多家知名家族資產(chǎn)，通過(guò)全方位資產(chǎn)配置策略覆蓋不同行業(yè)與不同階段及全球地區(qū)的投資機(jī)會(huì)。已成功投資全球80余個(gè)知名基金及280余家成功企業(yè)！?
直接投資：山東步長(zhǎng)藥業(yè)、健能隆醫(yī)藥?Generon、鳳凰醫(yī)療、美年大健康、慈銘體檢、愛(ài)康國(guó)賓、佳美口腔、七樂(lè)康藥業(yè)、快方送藥、快易檢、Waterstone Pharma.、San Valley Bio、安婕妤化妝品、易恒健康；3NT Medical (Israel)、Ornim Medical (Israel)、OncoResponse (US)、Eolo Medical (US)、Aravive Biologics (US)、VCP/ADVISORS (UK)、中德醫(yī)療、朝聚眼科、百度外賣、喜瑪拉雅FM、奇虎360、九櫻天下…投資期間協(xié)助公司并購(gòu)上下游企業(yè)；主導(dǎo)引進(jìn)國(guó)際關(guān)鍵技術(shù)落地被投企業(yè)國(guó)產(chǎn)化生產(chǎn)；協(xié)助被投企業(yè)取得國(guó)際大廠技術(shù)授權(quán)及技術(shù)轉(zhuǎn)移等。協(xié)助多家國(guó)內(nèi)上市制藥企業(yè)取得多項(xiàng)的國(guó)際藥品授權(quán)與合作等。
Mr. Syh focuses on healthcare industry investments and managing assets of family offices, he is on the board of directors in a number of biotech companies. Mr. Syh is currently managing a number of well-known family offices, leading and implementing a full-spectrum of strategies in different sectors and stages, and cross? regions, in U.S., EU, Israel and Asia. The global portfolio he worked on with success covers more than 80 investment funds and more than 280 direct investments portfolio companies.?As for Alvin Syh experience includes working as region head in Greater China for a US pharmaceutical company. During the time, he supervised in Greater China and parts of the US R&D of a drug which is licensed out to Novartis. Further, he lead the Asian team to licensing out and technology transferal of a class 1 controlled drug to the Taiwan government. He was also a advisor for:
* Taiwan’s Biological Industry Ministry of Economic Affairs* Industrial Taiwan Research Institute (ITRI),* Taiwan Pharmaceutical Manufacturer’s Association,